Golden
Seres Therapeutics

Seres Therapeutics

Seres Therapeutics is a microbiome therapeutics company that was founded in 2010 and headquartered in Cambridge, Massachusetts.

Seres Therapeutics is a microbiome therapeutics company headquartered in Cambridge, Massachusetts and was founded in 2010 by Noubar Afeyan and David Berry. Seres Therapeutics is using a discovery and design platform for developing new therapies using live bacteria for the treatment of diseases that are a result of microbiome deficiencies. Seres Therapeutics is focused on developing therapies for the treatment of Clostridium difficile infection (CDI), inflammatory bowel disease, and an oral microbiome therapy for improving the safety and efficacy of immunotherapies. 

Funding

Series A

On November 27, 2012 Seres Therapeutics closed their series A funding round with an undisclosed amount of funding from Flagship Pioneering and Enso Ventures.

Series B

On may 23, 2014 Seres Therapeutics closed their series B funding round with$10 million in funding from Mayo Clinic, Flagship Pioneering, Enso ventures, and Alexandria Venture. 

Series C

On December 2, 2014 Seres Therapeutics closed their series C funding round with $48 million in funding from Flagship Pioneering. 

Series D

On January 6, 2015 Seres Therapeutics closed their series D funding round with $65 million in funding from Nestlé Health Science. 



Timeline

People

Name
Role
LinkedIn

Barbara McGovern

Vice President, Medical Affairs



Carlo Tanzi

Vice President, Investor Relations and Corporate Communications



Carol Lewis-Cullinan

Vice President, Clinical Operations



David Berry

Co-Founder



David Cook

Executive Vice President, CSO



Eric Shaff

Executive Vice President, Chief Operating and Financial Officer



Henry Rath

Senior Vice President, Corporate Development



Jeff York

Vice President, Human Resources



Jim Weston

Senior Vice President, Regulatory Affairs



John Aunins

Executive Vice President, Bioprocesses & manufacturing and CTO



Kevin Horgan

Executive Vice President, Chief Medical Officer



Mathew Henn

Executive Vice president, Microbiome Research and Development



Noubar Afeyan

Co-Founder



Roger Pomerantz

President, CEO, and Chairman of the Board of Directors



Thomas DesRosier

Executive Vice President, Chief Legal Officer and Secretary



Further reading

Title
Author
Link
Type
Date









Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References